Skip to main content

Advertisement

Table 2 In vitro anticancer screening of the synthesized compounds against human lung carcinoma cell line (A-549)

From: Design, synthesis, and biological evaluation of novel N4-substituted sulfonamides: acetamides derivatives as dihydrofolate reductase (DHFR) inhibitors

Comp. no. Validity for sample conc. IC50 (μg mL−1)a IC50 (μM)a
500 250 125 62.50 31.25 15.60 7.80 3.90 2 1 0
5a 5.19 11.84 25.06 37.15 48.91 62.87 80.96 91.43 97.02 100 100 29.90 80.06
5b 5.38 11.97 24.02 36.59 47.38 63.20 78.15 87.56 94.03 98.76 100 28.60 70.88
5c 4.31 8.65 16.37 28.74 40.96 58.71 73.04 89.21 96.28 100 100 23.20 59.87
5d 2.65 5.34 10.26 19.45 28.73 39.04 57.26 71.89 85.22 92.34 100 10.90 26.72
5e 2.94 6.71 14.09 23.87 36.29 49.85 70.63 89.24 96.31 99.72 100 15.50 34.26
5f 4.23 9.86 20.15 32.76 45.13 59.38 75.04 82.38 91.75 97.43 100 25.80 57.91
5g 2.75 6.39 10.42 18.65 28.91 40.74 56.26 70.89 83.11 88.62 100 10.90 26.11
5h 2.86 5.43 12.87 22.96 34.53 47.28 65.39 80.72 89.86 97.13 100 14.40 34.41
5i 4.73 10.59 18.42 28.96 40.67 59.23 73.18 85.21 92.74 97.35 100 23.30 62.06
5j 2.98 6.74 10.85 19.73 26.8 37.28 49.06 70.31 84.15 91.38 100 7.60 18.74
5k 8.92 16.34 24.08 35.17 49.01 72.38 89.42 98.36 100 100 100 30.50 78.31
5l 1.89 4.37 8.76 19.04 30.63 43.86 59.12 76.44 90.63 96.42 100 12.40 30.25
5m 6.72 10.86 22.38 31.49 46.75 69.42 86.03 92.34 99.71 100 100 28.90 63.61
5n 4.86 9.73 19.48 31.72 45.29 64.18 80.63 92.34 97.23 100 100 27.30 61.00
5o 2.89 6.54 15.93 24.06 36.41 52.97 68.02 79.19 91.42 98.76 100 18.30 43.63
5p 3.69 8.71 18.63 29.46 41.87 54.06 71.32 87.14 95.20 99.73 100 20.70 49.23
6a 3.65 8.29 16.34 25.87 37.06 46.92 58.43 80.71 87.53 93.14 100 13.50 36.15
6b 6.14 13.65 25.38 37.25 56.41 79.84 92.36 98.6 100 100 100 41.70 103.35
6c 3.74 7.46 15.28 27.4 41.35 56.79 68.42 82.37 91.43 97.60 100 22.40 57.81
6d 4.08 6.82 11.43 19.46 30.67 43.20 59.13 71.44 85.12 92.37 100 12.20 29.91
6e 4.62 11.29 20.47 34.13 45.29 62.37 80.94 89.76 97.02 100 100 26.80 59.24
6f 6.31 13.45 19.75 31.42 47.23 71.94 89.56 97.13 100 100 100 29.40 65.99
6g 9.56 21.87 30.64 43.19 59.46 78.28 91.40 98.76 100 100 100 49.40 118.33
6h 1.98 4.87 9.72 19.93 28.61 40.72 63.18 79.43 90.64 97.39 100 12.30 29.39
6i 7.94 11.52 24.43 36.25 49.72 71.49 89.70 97.41 100 100 100 30.90 82.30
6j 3.87 7.96 16.20 27.85 41.79 54.03 71.48 88.60 96.23 100 100 20.70 51.05
6k 7.18 12.98 23.06 33.97 47.85 63.28 78.91 90.68 97.89 100 100 29.00 74.46
6l 6.74 14.35 21.88 35.46 46.29 58.17 78.03 86.36 94.12 98.78 100 26.30 64.16
6m 4.28 9.53 18.75 31.92 40.06 47.41 73.65 90.37 98.91 100 100 14.80 32.57
6n 11.82 23.48 30.51 41.3 47.42 60.31 82.42 97.14 100 100 100 28.07 62.72
6o 31.96 49.72 73.68 90.63 97.46 100 100 100 100 100 100 248.00 591.25
6p 2.79 6.28 13.91 25.04 37.18 52.94 68.29 84.67 92.84 98.25 100 18.50 44.00
5-FU 10.28 19.45 25.39 39.48 57.21 70.82 86.19 94.36 99.25 100 100 43.9 337.48
  1. IC50 value: concentration causing 50% inhibition of cell viability
  2. aMean of three results obtained from three experiments